Michelle Dalton

Michelle Dalton

Contributing Writer

Michelle Dalton, ELS, is an award-winning journalist who founded Dalton & Associates, Inc. in 2006. She has spent the past 19 years writing primarily about ophthalmology, covering everything from the business of ophthalmology to the latest in pharmacologic and technology advances.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
OIS@SECO In The Books

March 11 2020

OIS@SECO In The Books

Last week we heard firsthand at OIS@SECO’s second annual event just what it means to be innovative in the field of optometry. Leading off the ...
Read More
‘Start Up Nation’ a True Moniker

February 19 2020

‘Start Up Nation’ a True Moniker

Israel’s second name is “start-up nation,” and there are anywhere from 50-70 companies developing products for the eye care industry in Israel. From a monetary ...
Read More
We’ve Got Your BAK

December 11 2019

We’ve Got Your BAK

Imagine a world where you could use as much preservative as you needed in a prescription eye drop without ever having to worry it would ...
Read More
OIS INDEX Oyster Point

November 14 2019

Oyster Point Pharma Goes Public

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has ...
Read More
OIS@ASRS Reporter's Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

August 7 2019

OIS@ASRS Reporter’s Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

CHICAGO – This year’s OIS@ASRS jam-packed into one day presentations from early and late-stage retinal treatment developers, panels from key opinion leaders in industry and ...
Read More
Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

May 14 2019

Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

VANCOUVER – Novartis is one of the world’s largest ophthalmic pharmaceutical companies, with $4.6 billion in assets as part of the Medicines division, yet some ...
Read More
Protocol V, LEAVO Among Retina Highlights at ARVO

May 1 2019

Protocol V, LEAVO Among Retina Highlights at ARVO 2019

VANCOUVER – Leave it to ARVO 2019 – the Association for Research in Vision and Ophthalmology – to keep attendees waiting until mid-evening to hear ...
Read More
How Green Surgery Practices Are Reducing Greenhouse Gasses and Waste, and Cutting Costs

January 30 2019

How Green Surgery Practices Are Reducing Greenhouse Gasses and Waste, and Cutting Costs

Surgery in most high-income countries generates large quantities of waste. For instance, single-use disposable instruments are often used in a variety of surgery settings, but ...
Read More
Chasing Presbyopia Utopia

December 12 2018

Chasing Presbyopia Utopia: Four Innovators and Their Search for Ophthalmology’s ‘Holy Grail’

The numbers can be overwhelming: 1.8 billion people globally were living with presbyopia in 2015, 826 million of whom had near vision impairment because they ...
Read More
What Relaxed Gene Therapy Oversight Means

November 28 2018

Putting Relaxed NIH, FDA Oversight of Gene Therapies into Perspective

The first human gene therapy trial started in 1990, and over the course of that decade a multitude of questions about the safety and efficacy ...
Read More
MIGS Minus One: What’s Next?

September 12 2018

MIGS Minus One: What’s Next?

With Alcon’s voluntary withdrawal in late August of the CyPass MicroStent due to safety concerns, many have been wondering how the rest of the class ...
Read More
Dry Eye Panel Sees Promising Path Ahead

June 27 2018

How Newer Diagnostics and Devices Are Making Dry Eye Treatments an Easier Sell

WASHINGTON, DC – Treating flairs and fluctuations while employing steroid tapering for the treatment of dry eye was the hot topic during the dry eye ...
Read More